
Egetis Therapeutics Q4 - Approved in EU, launch in Germany in Q2

Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent approval in the EU. 2025 looks like an interesting year - with a launch in EU and a likely US filing.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Egetis Therapeutics Q4 - Approved in EU, launch in Germany in Q2